Bulbus Thunberg Fritillaria (zhe bei mu)
RadixStephania tetrandra (han fang ji)
Rhizoma Chuanxiong (chuan xiong)
Compound Zhebei Granules (CZG) can increase the clinical remission rate for refractory acute leukemia during chemotherapy. Using a randomised, double-blind and multi-central concurrent control clinical research project, the patients conformed with the diagnostic criteria, according to the drug randomised method, were divided into a CZG group and a control group. The patients of the two groups respectively took the observation drug or a placebo 3 days before chemotherapy, and the therapeutic effects were evaluated after one course of chemotherapy.
The clinical complete remission (CR) rate was 42.3% in the CZG group with a total effective rate of 73.2%, and it was 25.8% in the control group with a total effective rate of 53.0%.
Source
Li DY, Huang S, Chen XY. Clinical observation of Compound Zhebei Granule in improving the survival time of refractory acute leukaemia patients. Journal of Traditional Chinese Medicine. Volume 29, Issue 3, September 2009, Pages 190-194 doi:10.1016/S0254-6272(09)60063-7
Results demonstrated by Chen Xy, et al (2013) prove that the CZG in combination with chemotherapy can significantly improve chemotherapy remission rate after one cycle of treatment, showing good prospects for clinical application. In this multicenter double-blind, placebo-controlled clinical trial, they randomly assigned 238 patients who meet the diagnostic criteria of refractory acute leukaemia to receive chemotherapy combined with CZBG or chemotherapy plus placebo.
There was statistically significant difference between the two arms according to Z/Cmh test (P<0.05). In the Per Protocol Set (PPS), the CR, CR + PR rates were 33.67%, 52.04% respectively in chemotherapy plus CZG arm and 24.24%, 37.37% in control arm.
Source
Chen Xy, Hou L, Yang Sl, et al. Clinical study on Compound Zhe Bei Granules (CZG) combined with chemotherapy to improve the clinical efficacy of refractory acute leukaemia. Cancer Research. DOI: 10.1158/1538-7445.AM2013-4661 Published 15 April 2013
Compared with the single treatment of doxorubicin group the groups the doxorubicin and CZG with dosage classified by three types(high, middle, low) decreased IOD of P-glycoprotein (PGP) lung resistance protein (LRP) and multidrug resistance associated protein (MRP) in K562/ A02 tumour xenografts with statistical significance (p0.05).
There no LRP expression in K562/A02 tumour xenografts in five groups. The combination of CZG and doxorubicin can decrease the expression of P-gp、MRP in K562/A02 multidrug resistance tumour xenografts.
A drug-combination of Compound Zhe Bei Granule (CZG) and doxorubicin effects on the expression of Multidrug Resistance Associated Proteins in K562/A02 cell line multidrug resistance tumor xenografts in mice.
Source
Zheng Z, Wang X, Li Z-P, Zeng J-Q. 首届浙赣两省肿瘤研究交流会论文汇编 2012年
CZG combining chemotherapy could reduce the percentages of CD34+ CD123+ and CD33+ CD123+ LSC, which might improve the clinical efficacy of refractory or relapsed acute myeloid leukemia (AML).
Seventy-eight patients with AML received bone marrow aspiration and the percentages of CD34+ CD123+ and CD33+ CD123+ cells were tested using flow cytometry method. A total of 24 refractory or relapsed AML patients were enrolled and treated with one cycle of standard chemotherapy combined with CZG.
Compared with refractory or relapsed AML patients, patients achieved remission had a significant lower percentage of CD34+ CD123+ cells (P<0.01) and CD33+ CD123+ cells (P<0.01), indicating that controlling the leukemia stem cell (LSC) percentage may be important for patients with AML to achieve sustainable remission.
Source
Wang J, Lai Z-l, Chen Y-y, et al. Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia. Chinese Journal of Integrative Medicine. June 2016, Volume 22, Issue 6, pp 438-444
MDR